










## Booster protection against confirmed infections and severe disease data from Israel


(& evidence for waning 2<sup>nd</sup> dose immunity)


Israeli MOH, Gertner Institute, Hebrew university, Technion & Weizmann Institute of Science Sept. 1<sup>st</sup>, 2021

## Rate of adverse events following 3<sup>rd</sup> dose is lower than after 1<sup>st</sup> or 2<sup>nd</sup> doses so far (some under-reporting expected in all cases)

1<sup>st</sup> dose 2<sup>nd</sup> dose 3<sup>rd</sup> dose







## Clalit HMO study: adverse events are substantially higher after SARS-CoV-2 infection than after vaccination

